LAUSR

CONCORD is a programme for the global surveillance of cancer survival. In 2015, the second cycle of the program (CONCORD‐2) established long‐term surveillance of cancer survival worldwide, for the first time, in the largest cancer survival study published to date. CONCORD‐2 provided cancer survival trends for 25,676,887 patients diagnosed during the 15‐year period between 1995 and 2009 with 1 of 10 common cancers that collectively represented 63% of the global cancer burden in 2009. Herein, the authors summarize the past, describe the present, and outline the future of the CONCORD programme. They discuss the difference between population‐based studies and clinical trials, and review the importance of international comparisons of population‐based cancer survival. This study will focus on the United States. The authors explain why population‐based survival estimates are crucial for driving effective cancer control strategies to reduce the wide and persistent disparities in cancer survival between white and black patients, which are likely to be attributable to differences in access to early diagnosis and optimal treatment. Cancer 2017;123:4977‐81. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.